Thus, routine evaluation of sTTR levels may serve as a potential and informative biomarker of drug efficacy and treatment response at an individual level, reflecting TTR stability and a decrease in new amyloid formation in patients with amyloidosis. The gene discussed is TTR; the disease is amyloidosis.